Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1 / Phase 2NCT03026166
Official study title

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Study summary

The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedIpilimumab and Nivolumab

Plus 1 other study approaches.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 17, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?35 U.S. locations

Locations may change over time.

Who runs it?AbbVie

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
AbbVie
Interventions being studied
Drug: Ipilimumab; Drug: Nivolumab; Drug: Rovalpituzumab tesirine
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Small cell lung cancer (SCLC)→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Participants with histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC) with progressive disease after at least one platinum-based chemotherapeutic regimen and with evaluable or measurable disease
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate hematologic, hepatic, and renal function
Reasons someone may not be able to joinExclusion criteria
  • Has active, known, or suspected autoimmune disease
  • Had prior exposure to an immuno-oncology or pyrrolobenzodiazepine (PBD)-based drug

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Ucsd /Id# 161030La Jolla, California
  • Florida Hospital /ID# 161017Orlando, Florida
  • University Cancer & Blood Cent /ID# 161028Athens, Georgia
  • University of Chicago /ID# 161006Chicago, Illinois
  • The University of Kansas Clini /ID# 162915Fairway, Kansas
  • Washington University-School of Medicine /ID# 161011St Louis, Missouri
  • Rutgers Cancer Institute of NJ /ID# 161032New Brunswick, New Jersey
  • Memorial Sloan Kettering Cancer Center /ID# 161010New York, New York
  • Duke University Medical Center /ID# 161009Durham, North Carolina
  • Oregon Health and Science University /ID# 161029Portland, Oregon
  • Medical University of South Carolina /ID# 161007Charleston, South Carolina
  • Tennessee Oncology, PLLC /ID# 161012Nashville, Tennessee

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 17, 2020. Always confirm current availability with the study team.

View original record ↗